179 related articles for article (PubMed ID: 38339219)
1. A Cancer-Specific Monoclonal Antibody against HER2 Exerts Antitumor Activities in Human Breast Cancer Xenograft Models.
Kaneko MK; Suzuki H; Ohishi T; Nakamura T; Tanaka T; Kato Y
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339219
[TBL] [Abstract][Full Text] [Related]
2. Establishment of a Novel Cancer-Specific Anti-HER2 Monoclonal Antibody H
Kaneko MK; Suzuki H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2024 Apr; 43(2):35-43. PubMed ID: 38563783
[TBL] [Abstract][Full Text] [Related]
3. An Anti-HER2 Monoclonal Antibody H
Tateyama N; Asano T; Ohishi T; Takei J; Hosono H; Nanamiya R; Tanaka T; Sano M; Saito M; Kawada M; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2021 Aug; 40(4):184-190. PubMed ID: 34424760
[TBL] [Abstract][Full Text] [Related]
4. Defucosylated Monoclonal Antibody (H
Suzuki H; Ohishi T; Nanamiya R; Kawada M; Kaneko MK; Kato Y
Curr Issues Mol Biol; 2023 Sep; 45(10):7734-7748. PubMed ID: 37886932
[TBL] [Abstract][Full Text] [Related]
5. An Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H
Kato Y; Ohishi T; Takei J; Nakamura T; Sano M; Asano T; Sayama Y; Hosono H; Kawada M; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2020 Aug; 39(4):123-128. PubMed ID: 32552424
[TBL] [Abstract][Full Text] [Related]
6. Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H
Kato Y; Ohishi T; Yamada S; Itai S; Takei J; Sano M; Nakamura T; Harada H; Kawada M; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2019 Aug; 38(4):157-161. PubMed ID: 31199696
[TBL] [Abstract][Full Text] [Related]
7. H
Kato Y; Ohishi T; Sano M; Asano T; Sayama Y; Takei J; Kawada M; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2020 Jun; 39(3):61-65. PubMed ID: 32423281
[TBL] [Abstract][Full Text] [Related]
8. Antitumor Activities in Mouse Xenograft Models of Canine Fibroblastic Tumor by Defucosylated Mouse-Dog Chimeric Anti-HER2 Monoclonal Antibody (H77Bf).
Suzuki H; Asano T; Ohishi T; Yoshikawa T; Suzuki H; Mizuno T; Tanaka T; Kawada M; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2023 Feb; 42(1):34-40. PubMed ID: 36383106
[TBL] [Abstract][Full Text] [Related]
9. An Antihuman Epidermal Growth Factor Receptor 2 Monoclonal Antibody (H
Kato Y; Ohishi T; Takei J; Nakamura T; Kawada M; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2020 Aug; 39(4):135-139. PubMed ID: 32644843
[TBL] [Abstract][Full Text] [Related]
10. Defucosylated Mouse-Dog Chimeric Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody (H77Bf) Exerts Antitumor Activities in Mouse Xenograft Models of Canine Osteosarcoma.
Nanamiya R; Ohishi T; Suzuki H; Mizuno T; Yoshikawa T; Asano T; Tanaka T; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2023 Feb; 42(1):27-33. PubMed ID: 36399552
[TBL] [Abstract][Full Text] [Related]
11. Locally misfolded HER2 expressed on cancer cells is a promising target for development of cancer-specific antibodies.
Arimori T; Mihara E; Suzuki H; Ohishi T; Tanaka T; Kaneko MK; Takagi J; Kato Y
Structure; 2024 May; 32(5):536-549.e5. PubMed ID: 38460519
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activities against breast cancers by an afucosylated anti-HER2 monoclonal antibody H
Tanaka T; Suzuki H; Ohishi T; Kaneko MK; Kato Y
Cancer Sci; 2024 Jan; 115(1):298-309. PubMed ID: 37942574
[TBL] [Abstract][Full Text] [Related]
13. Establishment of H
Yamada S; Itai S; Nakamura T; Chang YW; Harada H; Suzuki H; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Dec; 36(6):287-290. PubMed ID: 29172998
[TBL] [Abstract][Full Text] [Related]
14. H
Takei J; Kaneko MK; Ohishi T; Kawada M; Harada H; Kato Y
Exp Ther Med; 2020 Aug; 20(2):846-853. PubMed ID: 32765652
[TBL] [Abstract][Full Text] [Related]
15. H
Itai S; Fujii Y; Kaneko MK; Yamada S; Nakamura T; Yanaka M; Saidoh N; Chang YW; Handa S; Takahashi M; Suzuki H; Harada H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Aug; 36(4):143-148. PubMed ID: 28700270
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
[TBL] [Abstract][Full Text] [Related]
17. Development of an Anti-HER2 Monoclonal Antibody H2Mab-139 Against Colon Cancer.
Kaneko MK; Yamada S; Itai S; Kato Y
Monoclon Antib Immunodiagn Immunother; 2018 Feb; 37(1):59-62. PubMed ID: 29315012
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.
Jain R; Rawat A; Verma B; Markiewski MM; Weidanz JA
J Natl Cancer Inst; 2013 Feb; 105(3):202-18. PubMed ID: 23300219
[TBL] [Abstract][Full Text] [Related]
19. Construction and evaluation of a novel humanized HER2-specific chimeric receptor.
Sun M; Shi H; Liu C; Liu J; Liu X; Sun Y
Breast Cancer Res; 2014 Jun; 16(3):R61. PubMed ID: 24919843
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab-based near-infrared photoimmunotherapy in xenograft mouse of breast cancer.
Yamashita S; Kojima M; Onda N; Yoshida T; Shibutani M
Cancer Med; 2023 Feb; 12(4):4579-4589. PubMed ID: 36259134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]